Cost-effectiveness analysis in markets with high fixed costs.

Area of Science:

• Health Economics
• Pharmaceutical Policy

Background:

• Market prices for pharmaceuticals often exceed marginal costs due to patent-induced monopoly power.
• Conducting cost-effectiveness analysis (CEA) requires accurate social cost estimation.

Purpose of the Study:

• To determine the social cost of pharmaceuticals, considering both marginal cost and the deadweight loss of revenue generation.
• To re-evaluate CEA recommendations for pharmaceutical interventions using accurate social costs.

Main Methods:

• Economic modeling to calculate the social cost of pharmaceuticals.
• Analysis of pharmaceutical pricing under public and private insurance mandates.
• Case studies on statin drugs and sorafenib for kidney cancer.

Main Results:

• The social cost of a branded drug is estimated at approximately 50% of the market price under public insurance.
• Under private insurance mandates, the social cost is estimated at about 33% of the market price.
• Accurate social cost accounting leads to more lenient CEA recommendations.

Conclusions:

• Standard CEA may overestimate the true cost of pharmaceuticals.
• Incorporating social costs into CEA provides a more accurate economic perspective for healthcare decision-making.
• Policy recommendations for drug approval and coverage should consider these refined cost-effectiveness measures.